NASDAQ:QDEL - Nasdaq - US2197981051 - Common Stock - Currency: USD
40.46
-0.57 (-1.39%)
The current stock price of QDEL is 40.46 USD. In the past month the price decreased by -8.73%. In the past year, price decreased by -13.71%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 28.89 | 234.01B | ||
ISRG | INTUITIVE SURGICAL INC | 80.74 | 211.07B | ||
BSX | BOSTON SCIENTIFIC CORP | 41.63 | 154.00B | ||
SYK | STRYKER CORP | 31.4 | 145.92B | ||
MDT | MEDTRONIC PLC | 16.84 | 115.33B | ||
BDX | BECTON DICKINSON AND CO | 16.35 | 65.30B | ||
EW | EDWARDS LIFESCIENCES CORP | 27.98 | 43.23B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 20.29 | 41.62B | ||
IDXX | IDEXX LABORATORIES INC | 40.25 | 37.07B | ||
DXCM | DEXCOM INC | 53.81 | 34.68B | ||
RMD | RESMED INC | 26.21 | 34.03B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 17.5 | 24.02B |
QuidelOrtho Corp. operates as a vitro diagnostics company. The company is headquartered in San Diego, California and currently employs 7,100 full-time employees. The firm sells its products directly to end users through a direct sales force and through a network of distributors, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, other point-of-care (POC) settings, blood banks and donor centers, as well as for individual, non-professional, over the counter (OTC) use. The firm provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics, Ortho Connect, Ortho Plus, Ortho Vision, QuickVue, Quidel, QuidelOrtho, QVue, Savanna, Sofia, Solana, Thyretain, Triage, Virena, Vitros among others. The company provides support for its customers across more than 130 countries and territories.
QUIDELORTHO CORP
9975 Summers Ridge Road
San Diego CALIFORNIA 92121 US
CEO: Douglas C. Bryant
Employees: 7100
Company Website: https://www.quidelortho.com/
Investor Relations: https://ir.quidel.com/
Phone: 18585521100
The current stock price of QDEL is 40.46 USD. The price decreased by -1.39% in the last trading session.
The exchange symbol of QUIDELORTHO CORP is QDEL and it is listed on the Nasdaq exchange.
QDEL stock is listed on the Nasdaq exchange.
15 analysts have analysed QDEL and the average price target is 54.5 USD. This implies a price increase of 34.69% is expected in the next year compared to the current price of 40.46. Check the QUIDELORTHO CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
QUIDELORTHO CORP (QDEL) has a market capitalization of 2.72B USD. This makes QDEL a Mid Cap stock.
QUIDELORTHO CORP (QDEL) currently has 7100 employees.
QUIDELORTHO CORP (QDEL) has a support level at 40.27 and a resistance level at 40.55. Check the full technical report for a detailed analysis of QDEL support and resistance levels.
The Revenue of QUIDELORTHO CORP (QDEL) is expected to grow by 0.53% in the next year. Check the estimates tab for more information on the QDEL EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
QDEL does not pay a dividend.
The PE ratio for QUIDELORTHO CORP (QDEL) is 21.87. This is based on the reported non-GAAP earnings per share of 1.85 and the current share price of 40.46 USD. Check the full fundamental report for a full analysis of the valuation metrics for QDEL.
The outstanding short interest for QUIDELORTHO CORP (QDEL) is 5.15% of its float. Check the ownership tab for more information on the QDEL short interest.
ChartMill assigns a technical rating of 1 / 10 to QDEL. When comparing the yearly performance of all stocks, QDEL is a bad performer in the overall market: 72.81% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to QDEL. Both the profitability and financial health of QDEL have multiple concerns.
Over the last trailing twelve months QDEL reported a non-GAAP Earnings per Share(EPS) of 1.85. The EPS decreased by -55.21% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -27.45% | ||
ROE | -58.57% | ||
Debt/Equity | 0.68 |
ChartMill assigns a Buy % Consensus number of 76% to QDEL. The Buy consensus is the average rating of analysts ratings from 15 analysts.
For the next year, analysts expect an EPS growth of 31.99% and a revenue growth 0.53% for QDEL